HC Wainwright Issues Pessimistic Estimate for KYTX Earnings

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Analysts at HC Wainwright cut their Q2 2025 earnings per share (EPS) estimates for Kyverna Therapeutics in a research note issued on Monday, May 19th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.92) per share for the quarter, down from their previous forecast of ($0.89). HC Wainwright currently has a "Neutral" rating and a $4.00 target price on the stock. The consensus estimate for Kyverna Therapeutics' current full-year earnings is ($3.29) per share. HC Wainwright also issued estimates for Kyverna Therapeutics' Q3 2025 earnings at ($0.77) EPS, Q4 2025 earnings at ($0.83) EPS and FY2025 earnings at ($3.56) EPS.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.21) by $0.18.

Separately, Morgan Stanley lowered their price objective on shares of Kyverna Therapeutics from $40.00 to $20.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 1st. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $18.33.

Kyverna Therapeutics Trading Down 8.1%

Shares of NASDAQ:KYTX traded down $0.20 during midday trading on Wednesday, reaching $2.27. The company had a trading volume of 524,822 shares, compared to its average volume of 421,119. The stock has a market cap of $98.11 million, a P/E ratio of -0.67 and a beta of 2.17. The company's 50 day moving average price is $2.12 and its 200 day moving average price is $3.16. Kyverna Therapeutics has a 52-week low of $1.78 and a 52-week high of $16.64.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Insight Holdings Group LLC raised its stake in Kyverna Therapeutics by 8.3% in the 1st quarter. Insight Holdings Group LLC now owns 989,054 shares of the company's stock valued at $1,909,000 after acquiring an additional 76,139 shares during the period. AQR Capital Management LLC bought a new stake in shares of Kyverna Therapeutics in the first quarter valued at approximately $137,000. Cubist Systematic Strategies LLC lifted its stake in shares of Kyverna Therapeutics by 31.1% during the 1st quarter. Cubist Systematic Strategies LLC now owns 68,628 shares of the company's stock valued at $132,000 after buying an additional 16,267 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Kyverna Therapeutics during the 1st quarter valued at approximately $92,000. Finally, Peapod Lane Capital LLC bought a new position in Kyverna Therapeutics in the 1st quarter worth approximately $765,000. Institutional investors own 18.08% of the company's stock.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.